# Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

> **NCT01711853** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 19 (actual)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** Dabigatran Etexilate

## Key facts

- **NCT ID:** NCT01711853
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711853, "Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01711853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*